Denosumab--an emerging treatment for postmenopausal osteoporosis (Q37679921)

21 August 2017

1 reference

title

Denosumab--an emerging treatment for postmenopausal osteoporosis (English)

1 reference

21 August 2017

0 references

E Michael Lewiecki

1

1 reference

PubMed ID

20095877

21 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Biological Therapy

21 August 2017

1 reference

21 August 2017

10

1 reference

21 August 2017

3

1 reference

21 August 2017

467-476

1 reference

Osteoporosis prevention, diagnosis, and therapy

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Hip fractures in the elderly: a world-wide projection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Perspective. How many women have osteoporosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

The crippling consequences of fractures and their impact on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Hip fracture in women without osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Longitudinal trends in use of bone mass measurement among older americans, 1999-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Compliance with drug therapies for the treatment and prevention of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Compliance with pharmacologic therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

The impact of compliance with osteoporosis therapy on fracture rates in actual practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

RANK ligand inhibition with denosumab for the management of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Pharmacokinetic aspects of biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

The role of the immune system in the pathophysiology of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Osteoclast precursors, RANKL/RANK, and immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

RANK is essential for osteoclast and lymph node development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003604708

10.1517/14712591003604708

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

20095877